PMID- 33389461
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20220111
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 53
IP  - 5
DP  - 2021 May
TI  - The efficacy and safety of roxadustat treatment for anemia in patients with 
      kidney disease: a meta-analysis and systematic review.
PG  - 985-997
LID - 10.1007/s11255-020-02693-7 [doi]
AB  - BACKGROUND: Anemia is a common complication for patients with kidney disease. 
      Roxadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor 
      (PHI), which is a newly approved oral drug for anemia. We performed this study to 
      build evidence regarding efficacy and safety of roxadustat in kidney disease 
      patients with or without dialysis. METHODS: We searched the databases of PubMed, 
      Embase, Cochrane library and clinicaltrials.gov from the inception to July 20, 
      2020. The randomized controlled trials (RCTs) which compared roxadustat with 
      placebo or other therapies in the treatment of anemia in kidney disease patients 
      were included. Data were extracted from eligible studies and pooled in a 
      meta-analysis model using RevMan5.3 and stata13.0 software. RESULTS: Eight RCTs 
      with 1010 patients were included in our analysis. We found that roxadustat 
      significantly increased hemoglobin (Hb) level (1.10 g/dL, 95% CI [0.52 g/dL, 
      1.67 g/dL], p = 0.0002), total iron-binding capacity (TIBC) (58.71 microg/dL, 95% CI 
      [44.10 microg/dL, 73.32 microg/dL], p < 0.00001), iron level (9.28 microg/dL, 95% CI 
      [0.11 microg/dL, 18.45 microg/dL], p = 0.05) compared with control group in kidney 
      disease patients. In addition, our result showed that a significant reduction in 
      hepcidin level (- 31.96 ng/mL, 95% CI [- 35.05 ng/mL, - 28.87 ng/mL], 
      p < 0.00001), ferritin (- 44.82 ng/mL, 95% CI [- 64.42 ng/mL, - 25.23 ng/mL], 
      p < 0.00001) was associated with roxadustat. No difference was found between 
      roxadustat and control group in terms of oral iron supplementation, adverse 
      events (AEs), serious adverse events (SAEs), infection, myocardial infraction, 
      stroke, heart failure and death. CONCLUSIONS: Roxadustat has higher mean Hb level 
      than placebo or EPO. Due to the short follow-up period and the lack of critical 
      data, more RCTs are needed to prove long-term safety and effectiveness of 
      roxadustat in the future.
FAU - Qie, Suhui
AU  - Qie S
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Jiao, Ning
AU  - Jiao N
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Duan, Kunfeng
AU  - Duan K
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Li, Jingxin
AU  - Li J
AD  - Department of Chinese Pharmacy, Hebei Maternity Hospital, 27 Shifeng Road, Qiaoxi 
      District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Liu, Guoqiang
AU  - Liu G
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China. 
      liugq1223@sohu.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210103
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 0 (Isoquinolines)
RN  - TE7660XO1C (Glycine)
RN  - X3O30D9YMX (roxadustat)
SB  - IM
MH  - Anemia/*drug therapy/*etiology
MH  - Glycine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Isoquinolines/adverse effects/*therapeutic use
MH  - Renal Insufficiency, Chronic/*complications
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anemia
OT  - Efficacy
OT  - Meta-analysis
OT  - Roxadustat
OT  - Safety
EDAT- 2021/01/04 06:00
MHDA- 2021/10/01 06:00
CRDT- 2021/01/03 20:40
PHST- 2020/05/10 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2021/01/04 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
PHST- 2021/01/03 20:40 [entrez]
AID - 10.1007/s11255-020-02693-7 [pii]
AID - 10.1007/s11255-020-02693-7 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2021 May;53(5):985-997. doi: 10.1007/s11255-020-02693-7. Epub 
      2021 Jan 3.